Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) General Information

Description

Proprietary rights of CUTX-101, a Copper Histidinate product candidate for the treatment of Menkes disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • New York, NY
  • United States
Primary Industry
Buildings and Property
Corporate Office
  • New York, NY
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)‘s full profile, request access.

Request a free trial

Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) Patents

Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022240726-A1 Copper histidinate compositions and uses thereof Pending 18-Mar-2021
CA-3212536-A1 Copper histidinate compositions and uses thereof Pending 18-Mar-2021
EP-4308104-A1 Copper histidinate compositions and uses thereof Pending 18-Mar-2021
EP-4308104-A4 Copper histidinate compositions and uses thereof Pending 18-Mar-2021
WO-2022197948-A1 Copper histidinate compositions and uses thereof Inactive 18-Mar-2021 A61P25/00
To view Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)’s complete patent history, request access »

Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)‘s full profile, request access.

Request a free trial

Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) FAQs

  • Where is Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) headquartered?

    Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) is headquartered in New York, NY.

  • What industry is Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) in?

    Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)’s primary industry is Buildings and Property.

  • Is Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) a private or public company?

    Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) is a Private company.

  • What is the current valuation of Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)?

    The current valuation of Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) is .

  • What is Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)’s current revenue?

    The current revenue for Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) is .

  • Who are Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)’s investors?

    Cyprium Therapeutics has invested in Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York).

  • When was Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) acquired?

    Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) was acquired on 24-Feb-2021.

  • Who acquired Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)?

    Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) was acquired by Sentynl Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process